PKN activation via transforming growth factor-β1 (TGF-β1) receptor signaling delays G2/M phase transition in vascular smooth muscle cells

Cell Cycle

Volumn 6, Issue 6, 2007, Pages 739-749

  Su, Chang ^a   Deaton, Rebecca A ^b   Iglewsky, Myriam A ^a   Valencia, Thomas G ^a   Grant, Stephen R ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cell cycle; G2 M phase; PKN; Smooth muscle; TGF 1

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; FASUDIL; PKN ENZYME; PROTEIN TYROSINE PHOSPHATASE; RHO KINASE; RHO KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; FLOW CYTOMETRY; IMMUNOPRECIPITATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; RNA INTERFERENCE; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

EID: 34047193277     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.6.3985     Document Type: Article

References (72)

1. Halayko AJ, Solway J. Molecular mechanisms of phenotypic plasticity in smooth muscle cells. J Appl Physiol 2001; 90:358-68.
2. Gordon D, Reidy MA, Benditt EP, Schwartz SM. Cell proliferation in human coronary arteries. Proc Natl Acad Sci USA 1990; 87:4600-04.
3. Glass R, Burnstock G. Immunohistochemical identification of cells expressing ATP-gated cation channels (P2X receptors) in the adult rat thyroid. J Anat 2001; 198(Pt 5):569-79.
4. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986; 314:488-500.
5. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: New therapeutic target for vascular proliferative disease. Circulation 1998; 98:82-89.
6. Coleman TR, Dunphy WG. Cdc2 regulatory factors. Curr Opin Cell Biol 1994; 6:877-82.
7. Brown KD, Coulson RM, Yen TJ, Cleveland DW. Cyclin-like accumulation and loss of the putative kinetochore motor CENP-E results from coupling continuous synthesis with specific degradation at the end of mitosis. J Cell Biol 1994; 125(6):1303-1312.
8. Chaturvedi P, Eng WK, Zhu Y, et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999; 18:4047-54.
9. Peng CY, Graves PR, Ogg S, et al. C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding. Cell Growth Differ 1998; 9:197-208.
10. Kohn EA, Ruth ND, Brown MK, Livingstone M, Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J Biol Chem 2002; 277:26553-64.
11. Toyoshima-Morimoto F, Taniguchi E, Nishida E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 2002; 3:341-48.
12. Qian YW, Erikson E, Taieb FE, Maller JL. The polo-like kinase Plx1 is required for activation of the phosphatase Cdc25C and cyclin B-Cdc2 in Xenopus oocytes. Mol Biol Cell 2001; 12:1791-99.
13. 2/M transition. Cell Cycle 2004; 3:733-37.
14. Morisaki N, Kawano M, Koyama N, et al. Effects of transforming growth factor-beta 1 on growth of aortic smooth muscle cells: Influences of interaction with growth factors, cell state, cell phenotype, and cell cycle. Atherosclerosis 1991; 88:227-34.
15. Goodman LV, Majack RA. Vascular smooth muscle cells express distinct transforming growth factor-beta receptor phenotypes as a function of cell density in culture. J Biol Chem 1989; 264:5241-44.
16. Waite KA, Eng C. From developmental disorder to heritable cancer: It's all in the BMP/TGF-beta family. Nat Rev Genet 2003; 4:763-73.
17. Tamaki K, Okuda S. Role of TGF-beta in the progression of renal fibrosis. Contrib Nephrol 2003; 139:44-65.
18. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 2003; 100:8430-35.
19. Miyazono K, Suzuki H, Imamura T. Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci 2003; 94:230-34.
20. Mehra A, Wrana JL. TGF-beta and the Smad signal transduction pathway. Biochem Cell Biol 2002; 80:605-22.
21. Wrana JL. Crossing Smads. Sci STKE 2000; 2000:RE1.
22. Watanabe H, de Caestecker MP, Yamada Y. Transcriptional cross-talk between Smad, ERK1/2, and p38 mitogen-activated protein kinase pathways regulates transforming growth factor-beta-induced aggrecan gene expression in chondrogenic ATDC5 cells. J Biol Chem 2001; 276:14466-73.
23. Wotton D, Massague J. Smad transcriptional corepressors in TGF beta family signaling. Curr Top Microbiol Immunol 2001; 254:145-64.
24. Quinn ZA, Yang CC, Wrana JL, McDermott JC. Smad proteins function as comodulators for MEF2 transcriptional regulatory proteins. Nucleic Acids Res 2001; 29:732-42.
25. 2-arrested Hep3B cells by TGF beta 1. Mol Carcinog 2003; 36:171-82.
26. Schmidt A, Gopfert C, Vlodavsky I, Volker W, Buddecke E. Induction of a hypertrophic growth status of coronary smooth muscle cells is associated with an overexpression of TGF-beta. Eur J Cell Biol 2002; 8:138-44.
27. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. Embo J 2000; 19:1745-54.
28. Iavarone A, Massague J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature 1997; 387:417-22.
29. Owens GK, Geisterfer AA, Yang YW, Komoriya A. Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol 1988; 107(2):771-780.
30. Funaba M, Zimmerman CM, Mathews LS. Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J Biol Chem 2002; 277(44):41361-41368.
31. Yamamoto T, Kozawa O, Tanabe K, et al. Involvement of p38 MAP kinase in TGF-beta-stimulated VEGF synthesis in aortic smooth muscle cells. J Cell Biochem 2001; 82(4):591-598.
32. Wicks SJ, Lui S, Abdel-Wahab N, Mason RM, Chantry A. Inactivation of smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase II. Mol Cell Biol 2000; 20(21):8103-8111.
33. Yakymovych I, Ten Dijke P, Heldin CH, Souchelnytskyi S. Regulation of Smad signaling by protein kinase C. Faseb J 2001; 15(3):553-555.
34. Mulder KM. Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Factor Rev 2000; 11(1-2):23-35.
35. Engel ME, McDonnell MA, Law BK, Moses HL. Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem 1999; 274(52):37413-37420.
36. Hartsough MT, Frey RS, Zipfel PA, et al. Altered transforming growth factor signaling in epithelial cells when ras activation is blocked. J Biol Chem 1996; 271(37):22368-22375.
37. Psichari E, Balmain A, Plows D, Zoumpourlis V, Pintzas A. High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by RhoA signaling. J Biol Chem 2002; 277(33):29490-29495.
38. Flynn P, Mellor H, Casamassima A, Parker PJ. Rho GTPase control of protein kinase C-related protein kinase activation by 3-phosphoinositide- dependent protein kinase. J Biol Chem 2000; 275(15):11064-11070.
39. Deaton RA, Su C, Valencia TG, Grant SR. Transforming growth factor-beta 1-induced expression of smooth muscle marker genes involves activation of PKN and p38 MAP kinase. J Biol Chem 2005.
40. Dong LQ, Landa LR, Wick MJ, et al. Phosphorylation of protein kinase N by phosphoinositide-dependent protein kinase-1 mediates insulin signals to the actin cytoskeleton. Proc Natl Acad Sci USA 2000; 97:5089-94.
41. Calautti E, Grossi M, Mammucari C, et al. Fyn tyrosine kinase is a downstream mediator of Rho/PRK2 function in keratinocyte cell-cell adhesion. J Cell Biol 2002; 156:137-48.
42. Torbett NE, Casamassima A, Parker PJ. Hyperosmotic-induced protein kinase N 1 activation in a vesicular compartment is dependent upon Rac1 and 3-phosphoinositide-dependent kinase 1. J Biol Chem 2003; 278:32344-32351.
43. Takahashi E, Berk BC. MAP kinases and vascular smooth muscle function. Acta Physiol Scand 1998; 164(4):611-621.
44. Sumioka K, Shirai Y, Sakai N, et al. Induction of a 55-kDa PKN cleavage product by ischemia/reperfusion model in the rat retina. Invest Ophthalmol Vis Sci 2000; 41(1):29-35.
45. Misaki K, Mukai H, Yoshinaga C, et al. PKN delays mitotic timing by inhibition of Cdc25C: Possible involvement of PKN in the regulation of cell division. Proc Natl Acad Sci USA 2001; 98(1):125-129.
46. Yoshinaga C, Mukai H, Toshimori M, Miyamoto M, Ono Y. Mutational analysis of the regulatory mechanism of PKN: The regulatory region of PKN contains an arachidonic acid-sensitive autoinhibitory domain. J Biochem (Tokyo) 1999; 126(3):475-484.
47. Rothman A, Kulik TJ, Taubman MB, Berk BC, Smith CW, Nadal-Ginard B. Development and characterization of a cloned rat pulmonary arterial smooth muscle cell line that maintains differentiated properties through multiple subcultures. Circulation 1992; 86(6):1977-1986.
48. Dalal SN, Schweitzer CM, Gan J, DeCaprio JA. Cytoplasmic localization of human cdc25C during interphase requires an intact 14-3-3 binding site. Mol Cell Biol 1999; 19(6):4465-4479.
49. Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000; 57(5):976-983.
50. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351(Pt 1):95-105.
51. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: An update. Biochem J 2003; 371(Pt 1):199-204.
52. 2/M checkpoint in SV40 large T antigen-immortalized embryonic fibroblast cells requires SHP-2 tyrosine phosphatase. J Biol Chem 2003; 278(44):42812-42820.
53. 2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997; 106(6):348-360.
54. Matsuzaki K, Date M, Furukawa F, et al. Regulatory mechanisms for transforming growth factor beta as an autocrine inhibitor in human hepatocellular carcinoma: Implications for roles of smads in its growth. Hepatology 2000; 32(2):218-227.
55. Damdinsuren B, Nagano H, Kondo M, et al. TGF-beta1-induced cell growth arrest and partial differentiation is related to the suppression of Id1 in human hepatoma cells. Oncol Rep 2006; 15(2):401-408.
56. Nakajima H, Nakajima HO, Dembowsky K, Pasumarthi KB, Field LJ. Cardiomyocyte cell cycle activation ameliorates fibrosis in the atrium. Circ Res 2006; 98(1):141-148.
57. Jiang Y, Cheng DW, Crook ED, Singh LP. Transforming growth factor-beta1 regulation of laminin gamma1 and fibronectin expression and survival of mouse mesangial cells. Mol Cell Biochem 2005; 278(1-2):165-175.
58. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000; 103(2):295-309.
59. Amano M, Chihara K, Nakamura N, Kaneko T, Matsuura Y, Kaibuchi K. The COOH terminus of Rho-kinase negatively regulates rho-kinase activity. J Biol Chem1999; 274:32418-24.
60. Eward KL, Van Ert MN, Thornton M, Helmstetter CE. Cyclin mRNA stability does not vary during the cell cycle. Cell Cycle 2004; 3:1057-61.
61. Mukai H. The structure and function of PKN, a protein kinase having a catalytic domain homologous to that of PKC. J Biochem (Tokyo) 2003; 133:17-27.
62. Piwnica-Worms H. Cell cycle: Fools rush in. Nature 1999; 401(6753):535, 537.
63. Takizawa CG, Morgan DO. Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol 2000; 1(2):658-65.
64. Kumagai A, Dunphy WG. Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science 1996; 273:1377-80.
65. Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G. Phosphorylation and activation of human cdc25-C by cdc2 - cyclin B and its involvement in the self-amplification of MPF at mitosis. Embo J 1993; 12:53-63.
66. Kumagai A, Yakowec PS, Dunphy WG. 14-3-3 proteins act as negative regulators of the mitotic inducer Cdc25 in Xenopus egg extracts. Mol Biol Cell 1998; 9:345-54.
67. Kumagai A, Dunphy WG. Binding of 14-3-3 proteins and nuclear export control the intracellular localization of the mitotic inducer Cdc25. Genes Dev 1999; 13:1067-1072.
68. Kaneko YS, Watanabe N, Morisaki H, et al. Cell-cycle-dependent and ATM-independent expression of human Chk1 kinase. Oncogene 1999; 18:3673-3681.
69. 2/M delay caused by arsenite. Mol Carcinog 2005; 43(1):1-12.
70. Takahashi M, Gotoh Y, Isagawa T, et al. Regulation of a mitogen-activated protein kinase kinase kinase, MLTK by PKN. J Biochem (Tokyo) 2003; 133:181-87.
71. Hagemann C, Blank JL. The ups and downs of MEK kinase interactions. Cell Signal 2001; 13:863-75.
72. Mukai H, Miyahara M, Sunakawa H, et al. Translocation of PKN from the cytosol to the nucleus induced by stresses. Proc Natl Acad Sci USA 1996; 93:10195-199.